Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Will TP53-mutated AML respond to immunotherapy?

Key clinical point: New research has shown increased immune infiltration in patients with TP53-mutated acute myeloid leukemia (AML).

Major finding: Patients with TP53-mutated AML had higher levels of T-cell infiltration, immune checkpoint molecules, and interferon-gamma signaling than patients with wild-type TP53.

Study details: Data from a discovery cohort of 147 patients with AML, a validation cohort of 140 patients, and samples from 60 patients with AML.

Disclosures: Dr. Rutella reported research support from NanoString Technologies, MacroGenics, and Kura Oncology.


Rutella S et al. SITC 2019, Abstract O3.